Compare Sanofi SA (SNY) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Vanguard Growth Index Fund ETF — how do they compare? Sanofi SA trades at $44.05 (market cap $104.83B), while Vanguard Growth Index Fund ETF trades at $86.07. The key difference: Sanofi SA pays a 5.5% dividend while Vanguard Growth Index Fund ETF pays none, and Vanguard Growth Index Fund ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| SNY | VUG | |
|---|---|---|
Market Cap | $104.83B | — |
Sector | Health | Sector/Thematic |
52-Week High | $52.34 | $90.29 |
52-Week Low | $41.33 | $70.00 |
Enterprise Value | $121.32B | — |
Dividend Yield | 5.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.
Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.
VUG trades at $85.32, up 0.06% on the day, with technical indicators showing a bearish bias as moving averages signal selling pressure while oscillators remain neutral. The ETF's growth-focused strategy, concentrated in large-cap U.S. companies, benefits from a low expense ratio of 0.03% and a decade-long track record of strong returns, though key financial ratios are not disclosed in the provided data. Recent news highlights its appeal for long-term investors seeking exposure to growth stocks.
The outlook for VUG is mixed, with technical weakness offset by positive sentiment for long-term growth potential. Risks include high tech concentration and market volatility, but analyst coverage emphasizes its cost efficiency and diversification benefits for buy-and-hold strategies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →
